sb 202190 and birb 796
sb 202190 has been researched along with birb 796 in 11 studies
Research
Studies (11)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Atteridge, CE; Azimioara, MD; Benedetti, MG; Biggs, WH; Carter, TA; Ciceri, P; Edeen, PT; Fabian, MA; Floyd, M; Ford, JM; Galvin, M; Gerlach, JL; Grotzfeld, RM; Herrgard, S; Insko, DE; Insko, MA; Lai, AG; Lélias, JM; Lockhart, DJ; Mehta, SA; Milanov, ZV; Patel, HK; Treiber, DK; Velasco, AM; Wodicka, LM; Zarrinkar, PP | 1 |
| Alessi, DR; Arthur, JS; Bain, J; Cohen, P; Elliott, M; Hastie, CJ; Klevernic, I; McLauchlan, H; Plater, L; Shpiro, N | 1 |
| Atteridge, CE; Campbell, BT; Chan, KW; Ciceri, P; Davis, MI; Edeen, PT; Faraoni, R; Floyd, M; Gallant, P; Herrgard, S; Hunt, JP; Karaman, MW; Lockhart, DJ; Milanov, ZV; Morrison, MJ; Pallares, G; Patel, HK; Pritchard, S; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
| Domeyer, DM; Hauser, DR; Kinkel, K; Laufer, SA; Liedtke, AJ | 1 |
| Hajduk, PJ; Johnson, EF; Kifle, L; Merta, PJ; Metz, JT; Soni, NB | 1 |
| Russu, WA; Shallal, HM | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Kok, JJ; Loomans, EE; Nelissen, RL; van der Lee, MM; Zaman, GJ | 1 |
| Hill, NT; Kadakia, M; Lee, M; Leonard, MK; Shamma, HN; Zhang, J | 1 |
| Browne, AJ; Göbel, A; Hofbauer, LC; Rachner, TD; Rauner, M; Thiele, S | 1 |
| Brábek, J; Čermák, V; Kolomazníková, V; Merta, L; Palušová, V; Rösel, D; Škarková, A; Uldrijan, S | 1 |
Other Studies
11 other study(ies) available for sb 202190 and birb 796
| Article | Year |
|---|---|
A small molecule-kinase interaction map for clinical kinase inhibitors.
Topics: Benzamides; Drug Design; Escherichia coli; Escherichia coli Proteins; Imatinib Mesylate; Microchemistry; Pharmaceutical Preparations; Piperazines; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Pyrimidines | 2005 |
The selectivity of protein kinase inhibitors: a further update.
Topics: Amino Acid Sequence; Animals; Cell Line; Drug Design; Enzyme Activation; Humans; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Recombinant Proteins; Spodoptera | 2007 |
A quantitative analysis of kinase inhibitor selectivity.
Topics: Binding Sites; Enzyme Activation; Humans; Phosphotransferases; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Proteome; Quantitative Structure-Activity Relationship | 2008 |
Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region.
Topics: Drug Design; Humans; Imidazoles; Molecular Mimicry; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Structure-Activity Relationship | 2008 |
Navigating the kinome.
Topics: Drug Design; Pharmacogenetics; Protein Kinases; Proteome; Systems Biology | 2011 |
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship | 2011 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Enzyme fragment complementation binding assay for p38alpha mitogen-activated protein kinase to study the binding kinetics of enzyme inhibitors.
Topics: Animals; Cell Line; Cell Line, Tumor; Dose-Response Relationship, Drug; Green Fluorescent Proteins; Humans; Imidazoles; Kinetics; Mitogen-Activated Protein Kinase 14; Molecular Structure; Naphthalenes; Peptide Fragments; Protein Binding; Protein Kinase Inhibitors; Protein Transport; Pyrazoles; Pyridines; Recombinant Fusion Proteins; Structure-Activity Relationship; Surface Plasmon Resonance | 2006 |
1α, 25-Dihydroxyvitamin D₃ and the vitamin D receptor regulates ΔNp63α levels and keratinocyte proliferation.
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cholecalciferol; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Keratinocytes; Naphthalenes; p38 Mitogen-Activated Protein Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyridines; Receptors, Calcitriol; RNA Interference; RNA, Small Interfering; Signal Transduction; Skin Neoplasms; Transcription Factors; Tumor Suppressor Proteins | 2015 |
p38 MAPK regulates the Wnt inhibitor Dickkopf-1 in osteotropic prostate cancer cells.
Topics: Antibodies, Neutralizing; Cell Differentiation; Cell Line, Tumor; Down-Regulation; Humans; Imidazoles; Intercellular Signaling Peptides and Proteins; Male; Mitogen-Activated Protein Kinase 11; Mitogen-Activated Protein Kinase 12; Mitogen-Activated Protein Kinase 14; Naphthalenes; p38 Mitogen-Activated Protein Kinases; Prostatic Neoplasms; Pyrazoles; Pyridines; RNA Interference; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Wnt3A Protein | 2016 |
RNA-seq Characterization of Melanoma Phenotype Switch in 3D Collagen after p38 MAPK Inhibitor Treatment.
Topics: Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Collagen; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Ontology; Humans; Imidazoles; Melanoma; Naphthalenes; p38 Mitogen-Activated Protein Kinases; Phenotype; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; RNA-Seq; Tumor Microenvironment | 2021 |